In the Special Content Considerations section of the AMCP Format for Formulary Dossiers, the first topic is Comparative Effectiveness Research. While most manufacturers provide evidence from randomized, controlled trials as an essential step in the product’s life cycle, It is recommended that manufacturers provide evidence from comparative effectiveness research (CER) as soon as it’s available.
Check back for more information on changes in the new AMCP Format for Formulary Submissions. If you need any assistance with adjusting your dossiers to meet the new guidance, let us know: 877-477-0977 or https://medcommunications.com/contact-us/
#AMCP #dossierwriting #managedcare